Teduglutide — Discount Pricing

Other medications in Digestive Health

• Tegaserod
• Ustekinumab
• Vedolizumab
• Adalimumab
• Alosetron
• Bisacodyl
• Budesonide (Crohn)
• Certolizumab

About Teduglutide

Teduglutide is a vital medication specifically designed for individuals living with Short Bowel Syndrome (SBS), helping to improve nutrient absorption and reduce the need for parenteral support. At TheDrugClub, we recognize the substantial financial burden that specialized treatments can impose. Our membership program is dedicated to providing significant savings on crucial prescriptions like Teduglutide, aiming to make your essential healthcare more accessible and affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Teduglutide is approved for (FDA label)

GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 5, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Teduglutide (FDA label)

For Injection: 5 mg teduglutide as a white lyophilized powder for reconstitution in a single-dose vial supplied with 0.5 mL Sterile Water for Injection in a single-dose prefilled syringe. For injection: 5 mg teduglutide in a single-dose vial supplied with 0.5 mL Sterile Water for Injection in a single-dose prefilled syringe. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Teduglutide (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: Acceleration of Neoplastic Growth [see Warnings and Precautions ( 5.1 )] Intestinal Obstruction [see Warnings and Precautions ( 5.2 )] Biliary and Pancreatic Disease [see Warnings and Precautions ( 5.3 )] Fluid Imbalance and Fluid Overload [see Warnings and Precautions ( 5.4 )] Most common adverse reactions (≥10%) are: abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload, and hypersensitivity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Adults Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.